<DOC>
	<DOCNO>NCT02340195</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics property idalopirdine follow multiple dose patient renal impairment compare healthy subject</brief_summary>
	<brief_title>Pharmacokinetic Properties Idalopirdine ( Lu AE58054 ) Subjects With Without Impaired Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Men woman age 50 75 year ( inclusive ) BMI ≥18.5 kg/m2 ≤32 kg/m2 Screening Visit . Group A : Patients severe renal impairment renal impairment ( creatinine clearance ( ClCr ) ≤29 mL/min ) Group B : Healthy subject normal kidney function ( creatinine clearance ( ClCr ) ≥90 mL/min , inclusive ) Group C : Patients moderate renal impairment ( ( creatinine clearance 30 59 mL/min , inclusive ) Group D : Patients mild renal impairment ( Creatinine clearance 60 89 mL/min , inclusive ) •The subject take disallowed medication &lt; 1 week prior first dose IMP &lt; 5 halflives prior first dose IMP disallow medication take , whichever long ) Other protocol define inclusion exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Kidney impairment</keyword>
</DOC>